Premium
Daunorubicin therapy in adult acute lymphatic leukemia
Author(s) -
Bloomfield Clara D.,
Brunning Richard D.,
Kennedy B. J.
Publication year - 1972
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197207)30:1<47::aid-cncr2820300108>3.0.co;2-m
Subject(s) - daunorubicin , medicine , prednisone , leukemia , lymphatic leukemia , acute leukemia , acute lymphocytic leukemia , lymphatic system , gastroenterology , immunology , lymphoblastic leukemia
Twelve adults with acute lymphatic leukemia, all but one of whom had relapsed while being treated with the usual antileukemic agents, were treated with daunorubicin and prednisone. Two complete and three partial remissions were obtained. The average duration of remission was 3 months. Daunorubicin was especially useful in prolonging survival in the pathologic type designated acute, rather than subacute, lymphocytic leukemia. Regardless of the initial response, no patient treated a second time with daunorubicin obtained a second remission. There are seven reports in the literature describing 19 adults with acute lymphatic leukemia treated with daunorubicin alone or with prednisone. Our results indicate a less favorable response to daunorubicin than did these earlier reports. However, daunorubicin does appear to be a useful agent in adults with acute lymphatic leukemia resistant to conventional leukemia therapy.